Novavax, moving closer to commercializing its flu vaccines, will raise $21 million in a secondary stock offering to fund continued research. (NVAX)
National Business News - Local Business News | bizjournals, Biz Journals
Fri, 11/20/2009 - 8:36am
Novavax, moving closer to commercializing its flu vaccines, will raise $21 million in a secondary stock offering to fund continued research. (NVAX)